Minapharm Pharmaceuticals announced consolidated and standalone earnings results for the first nine months of 2019. For the period, consolidated net profit fell to EGP 73.9 million compared with EGP 117.39 million in the year-before period. The company recorded EGP 1.503 billion in revenues over the nine-month period, slightly lower than EGP 1.505 billion a year ago. The company posted a standalone profit of EGP 27.9 million over the first three quarters of 2019, a year-on-year drop from EGP 42.65 million.